🇺🇸 FDA
Patent

US 7199157

Use of treprostinil to improve kidney functions

granted A61KA61K31/5575A61K9/006

Quick answer

US patent 7199157 (Use of treprostinil to improve kidney functions) held by United Therapeutics Corporation expires Mon Mar 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United Therapeutics Corporation
Grant date
Tue Apr 03 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/5575, A61K9/006, A61K9/0073, A61P